Abstract Background: IgG4-related disease (IgG4-RD) is a rare, immune-mediated fibroinflammatory condition characterized by tissue infiltration with IgG4-positive plasma cells. While solid organ involvement is well documented, data on hematologic manifestations and associated outcomes remain limited. Understanding hematological burden and real-world treatment patterns is essential to guide comprehensive management. Methods: We conducted a multicenter, retrospective cohort study using the TriNetX Research Network, comprising electronic health records from multiple U.S. healthcare systems. Adults (≥18 years) with a diagnosis of IgG4-RD (ICD-10 codes) were included. Patients with a prior diagnosis of hematologic malignancy were excluded. Demographic characteristics, hematologic manifestations, treatment patterns, and overall mortality were assessed. The median follow-up duration was 519 days. Results: A total of 2,596 patients with IgG4-RD were identified, of whom 554 (21.3%) exhibited at least one hematologic manifestation. The mean age was 58.1 ± 15.9 years; 53% were male (n=1,379), and 57% were White (n=1,492). Hypertension was the most common comorbidity (44%, n=1,136). Among those with hematologic involvement, key manifestations included lymphadenopathy (n=605, 23.3%), hepatomegaly (n=114, 4.4%), splenomegaly (n=73, 2.8%), eosinophilia (n=71, 2.7%), pancytopenia (n=31, 1.2%), hypergammaglobulinemia (n=71, 2.7%), and monoclonal gammopathy (n=86, 3.3%). Regarding outcomes, 127 of 2,596 patients (4.9%) died during the follow-up period. Among those with hematologic manifestations, 36 of 554 (6.5%) died, indicating a numerically higher mortality rate in this subgroup. Treatment data revealed that all patients received corticosteroids as initial therapy. Additionally, 531 patients (20.4%) received steroid-sparing immunosuppressants. The most used agents included rituximab (6%), azathioprine (6%), mycophenolate mofetil (5%), and methotrexate (3%). Conclusion: In this large, real-world cohort of patients with IgG4-RD, hematologic manifestations were observed in over one-fifth of patients and were associated with a numerically higher mortality rate. Lymphadenopathy was the most common hematologic feature. Despite the widespread use of corticosteroids, a substantial proportion of patients required steroid-sparing agents. These findings highlight the hematologic complexity of IgG4-RD and underscore the need for multidisciplinary management and prospective studies focused on hematologic outcomes.
Re-Evaluating Chemotherapy Dosing Strategies for Ovarian Cancer: Impact of Sarcopenia
We investigated the impact of sarcopenia on adjuvant chemotherapy dosing in advanced epithelial ovarian cancer (EOC). The chemotherapy dosing and toxicity of 173 eligible patients who underwent cytoreductive surgery and adjuvant chemotherapy at a single institution were analyzed. Patients with a skeletal muscle index less than 39 cm2/m2 measured on a CT scan were considered sarcopenic. Sarcopenic and non-sarcopenic patients were compared with regard to relative dose intensity (RDI), completion of scheduled chemotherapy, toxicity, and survival. A total of 62 (35.8%) women were sarcopenic. Sarcopenic women were less likely to complete at least six cycles of chemotherapy (83.9% vs. 95.5%, p = 0.02). The mean RDI for both carboplatin (80.4% vs. 89.4%, p = 0.03) and paclitaxel (91.9% vs. 104.1%, p = 0.03) was lower in sarcopenic patients compared to non-sarcopenic patients. Despite these differences in chemotherapy, there was no difference in neutropenia or median overall survival (3.99 vs. 4.57 years, p = 0.62) between the sarcopenic and non-sarcopenic women, respectively. This study highlights the importance of considering lean body mass instead of body weight or surface area in chemotherapy dosing formulas for sarcopenic women with advanced EOC. Further research is needed to optimize chemotherapy strategies based on individual body composition, potentially leading to improved dosing strategies in this population.